Determinants of HIV drug resistance and public health implications in low- and middle-income countries

Antiviral Therapy

Volumn 17, Issue 6, 2012, Pages 941-953

  Bertagnolio, Silvia ^a   De Luca, Andrea ^b   Vitoria, Marco ^a   Essajee, Shaffiq ^c   Penazzato, Martina ^d   Hong, Steven Y ^e   McClure, Craig ^f   Duncombe, Chris ^g   Jordan, Michael R ^e  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c CLINTON HEALTH ACCESS INITIATIVE   (United States)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNICEF   (United States)

^g BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRY; DISEASE SURVEILLANCE; DRUG EFFICACY; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOTHER CHILD RELATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SOCIAL DISCRIMINATION; SOCIAL STIGMA; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

ADMINISTRATIVE PERSONNEL; ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; INCOME; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PATIENT COMPLIANCE; POPULATION SURVEILLANCE; PUBLIC HEALTH; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 84865771258     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2320     Document Type: Review

References (119)

1. Joint United Nations Programme on HIV/AIDS. Together we will end AIDS. (Updated 2012. Accessed 18 July 2012.) Available from http://www.unaids.org/en/ media/unaids/contentassets/documents/epidemiology/2012/20120718- togetherwewillendaids-en.pdf
2. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011; 365:637-646.
3. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
4. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
5. Violin M, Cozzi-Lepri A, Velleca R, et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004; 18:227-235.
6. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197:867-870.
7. World Health Organization. World Health Organization HIV drug resistance report 2012. (Updated 2012. Accessed 29 July 2012.) Available from http://www.who.int/hiv/pub/drugresistance/report2012/en/index.html
8. Sigaloff KC, Mandaliya K, Hamers RL, et al. High prevalence of transmitted antiretroviral drug resistance among newly hiv type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retroviruses 2012; doi: 10.1089/aid.2011.0348.
9. Somda A, Sangare L, Soro M, et al. Surveillance of transmitted drug resistant HIV among young pregnant women in Ouagadougou, Burkina Faso. Clin Infect Dis 2012; 54 Suppl 4:S317-S319.
10. Hunt GM, Ledwaba J, Basson A, et al. Surveillance of transmittedHIV-1 drug resistance in Gauteng and KwaZulu-Natal provinces,South Africa from 2005-2009. Clin Infect Dis 2012; 54 Suppl 4:S334-S338.
11. Duc NB, Hein BT, Wagar N, et al. Surveillance of transmitted HIV drug resistance using matched plasma and dried blood spot specimens from voluntary counseling and testing sites in Ho Chi Minh City, Vietnam, 2007-2008. Clin Infect Dis 2012; 54 Suppl 4:S343-S347.
12. Liao L, Xing H, Dong Y, et al. Surveys of transmitted HIV drug resistance in 7 geographic regions in China, 2008-2009. Clin Infect Dis 2012; 54 Suppl 4:S320-S323.
13. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12:307-317.
14. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11:363-371.
15. World Health Organization. Antiretroviral therapy for hiv infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization 2010.
16. Mills EJ, Nachega JB. A wake-up call for global access to salvage HIV drug regimens. Lancet 2007; 370:1885-1887.
17. Jordan MR. Assessments of HIV drug resistance mutations in resource-limited settings. Clin Infect Dis 2011; 52:1058-1060.
18. Kozal MJ, Hullsiek KH, Macarthur RD, et al. The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007; 8:357-370.
19. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
20. Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G. Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review. Dig Liver Dis 2006; 38:363-373.
21. Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS. 2008; 3:653-659.
22. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23:1109-1118.
23. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis 2007; 196 Suppl 3:S449-S456.
24. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
25. Clinton Health Access Initiative. Antiretroviral (ARV) price list. (Updated November 2010. Accessed 29 July 2012.) Available from http://www.clintonhealthaccess.org/files/chai-arv-priceList-201011-english.pdf
26. Bennett DE, Jordan MR, Bertagnolio S, et al. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis 2012; 54 Suppl 4:S280-S289.
27. Hirnschall G, Schwartlander B. Treatment 2.0: catalysing the next phase of scale-up. Lancet 2011; 378:209-211.
28. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
29. Soria A, Porten K, Fampou-Toundji JC, et al. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther 2009; 14:339-347.
30. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
31. Smith CJ, Phillips AN, Hill T, et al. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. J Infect Dis 2005; 192:1387-1397.
32. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
33. Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008; 22:2117-2125.
34. Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis 2009; 48:115-122.
35. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002; 18:835-838.
36. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191-1201.
37. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
38. Luber AD. Genetic barriers to resistance and impact on clinical response. J Int AIDS Soc 2005; 7:69.
39. Cozzi-Lepri A, Paredes R, Phillips AN, et al. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI. HIV Med 2012; 13:62-72.
40. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-722.
41. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 2009; 52:209-221.
42. Maserati R, De Silvestri A, Uglietti A, et al. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS 2010; 24:1013-1018.
43. Svicher V, Alteri C, Artese A, et al. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr 2010; 55:336-344.
44. Tang MW, Kanki PJ, Shafer RW. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis 2012; 54:862-875.
45. Rey D, Hoen B, Chavanet P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009; 63:380-388.
46. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther 2011; 16:339-348.
47. von Wyl V, Yerly S, Boni J, et al. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis 2012; 54:131-140.
48. Zolfo M, Schapiro JM, Phan V, et al. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01-AE-infected cohort. AIDS Res Hum Retroviruses 2011; 27:727-735.
49. Goetz MB, Ferguson MR, Han X, et al. Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. J Acquir Immune Defic Syndr 2006; 43:541-549.
50. De Luca A, Di Giambenedetto S, Romano L, et al. Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J Infect Dis 2006; 193:1219-1222.
51. De Luca A, Giambenedetto SD, Trotta MP, et al. Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine. J Infect Dis 2007; 196:1645-1653.
52. Amon JJ. Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs. Global Health 2008; 4:5.
53. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2005; 2:e100.
54. Chomat AM, Wilson IB, Wanke CA, Selvakumar A, John KR, Isaac R. Knowledge, beliefs, and health care practices relating to treatment of HIV in Vellore, India. AIDS Patient Care STDS 2009; 23:477-484.
55. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther 2003; 8:339-346.
56. Juday T, Gupta S, Grimm K, Wagner S, Kim E. Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials 2011; 12:71-78.
57. World Health Organization. Short-term priorities for antiretroviral drug optimization: meeting report. 18-19 April 2011, London, UK. Geneva: World Health Organization 2011.
58. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14:1039-1043.
59. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530-539.
60. Andreotti M, Guidotti G, Galluzzo CM, et al. Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. AIDS 2007; 21:2360-2362.
61. Arrivé E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-1021.
62. Hunt GM, Coovadia A, Abrams EJ, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 2011; 25:1461-1469.
63. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363:1510-1520.
64. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564-573.
65. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011; 25:843-850.
66. Hauser A, Mugenyi K, Kabasinguzi R, Kuecherer C, Harms G, Kunz A. Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS ONE 2011; 6:e20357.
67. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20:F9-F13.
68. Coutsinos D, Invernizzi CF, Moisi D, et al. A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS ONE 2011; 6:e20208.
69. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-87.
70. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33:1417-1423.
71. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007; 45:4-8.
72. Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008; 24:1263-1268.
73. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-231.
74. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347.
75. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-1183.
76. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-1058.
77. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006; 43:78-84.
78. Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥200 cells/microl. AIDS 2006; 20:1117-1123.
79. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-690.
80. Crane JT, Kawuma A, Oyugi JH, et al. The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS Behav 2006; 10:437-442.
81. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003; 34:281-288.
82. Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS ONE 2010; 5:e10340.
83. Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 2004; 20:1053-1056.
84. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38:1311-1316.
85. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-971.
86. Marcellin F, Boyer S, Protopopescu C, et al. Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaounde, Cameroon (EVAL survey, ANRS 12-116). Trop Med Int Health 2008; 13:1470-1478.
87. Eholié SP, Tanon A, Polneau S, et al. Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2007; 45:355-358.
88. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav 2010; 14:778-784.
89. Foster C, Judd A, Tookey P, et al. Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS 2009; 23:159-166.
90. Temple ME, Koranyi KI, Nahata MC. Gastrostomy tube placement in nonadherent HIV-infected children. Ann Pharmacother 2001; 35:414-418.
91. King JR, Yogev R, Aldrovandi G, Chadwick E, Acosta EP. Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube. HIV Clin Trials 2004; 5:288-293.
92. Nahirya-Ntege P, Cook A, Vhembo T, et al. Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS ONE 2012; 7: e36186.
93. Nyandiko WM, Ayaya S, Nabakwe E, et al. Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. J Acquir Immune Defic Syndr 2006; 43:418-425.
94. Wolfe WR, Weiser SD, Leiter K, et al. The impact of universal access to antiretroviral therapy on HIV stigma in Botswana. Am J Public Health 2008; 98:1865-1871.
95. Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDS 2006; 20:359-368.
96. Van Tam V, Pharrisa A, Thorsona A, Alfvena T, Larssona M. 'It is not that I forget, it's just that I don't want other people to know': barriers to and strategies for adherence to antiretroviral therapy among HIV patients in Northern Vietnam. AIDS Care 2011; 23:139-145.
97. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 2007; 45:1492-1498.
98. Nabukeera-Barungi N, Kalyesubula I, Kekitiinwa A, Byakika-Tusiime J, Musoke P. Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala. Ann Trop Paediatr 2007; 27:123-131.
99. Bertagnolio S. Minimizing the selection and transmission of drug resistant HIV: assessment and interventions in resource limited settings. IAS Conference. 17-20 July 2011, Rome, Italy.
100. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010; 24:2263-2270.
101. Keiser O, Tweya H, Boulle A, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23:1867-1874.
102. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:500-506.
103. Pujades-Rodríguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA 2010; 304:303-312.
104. Martinez J, Harper G, Carleton RA, et al. The impact of stigma on medication adherence among HIV-positive adolescent and young adult females and the moderating effects of coping and satisfaction with health care. AIDS Patient Care STDS 2012; 26:108-115.
105. Harries AD, Zachariah R, Lawn SD, Rosen S. Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010; 15 Suppl 1:70-75.
106. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15 Suppl 1:1-15.
107. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 2009; 4:e5790.
108. Losina E, Toure H, Uhler LM, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Cote d'Ivoire appraisal. PLoS Med 2009; 6:e1000173.
109. 3: assessment of need following changes in treatment guidelines. Clin Infect Dis 2011; 53:817-825.
110. Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19:487-494.
111. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50:98-105.
112. Baggaley RF, Powers KA, Boily MC. What do mathematical models tell us about the emergence and spread of drug-resistant HIV? Curr Opin HIV AIDS. 2011; 6:131-140.
113. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Recommendations for a public health approach (2010 version). Geneva, World Health Organization 2010.
114. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of tripleantiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8:e1000430.
115. Church JD, Omer SB, Guay LA, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 2008; 198:1075-1082.
116. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13 Suppl 2:1-13.
117. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13 Suppl 2:15-23.
118. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl 2:25-36.
119. Myatt M, Bennett DE. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 2008; 13 Suppl 2:37-48.